September 2004
Biotech Business;Sep2004, Vol. 17 Issue 9, p5
Trade Publication
Reports on the agreement of the U.S. Food and Drug Administration on the protocols constituting the phase III program of Alexion Pharmaceuticals Incorporated for its drug eculizumab. Overview of the phase III trial program; Results of the first trial performed on patients with chronic orphan blood disorder Paroxysmal Nocturnal Hemoglobinuria (PNH); Information on PNH; Background of the company.


Related Articles

  • ALEXION ENROLLS ECULIZUMAB PHASE III SHEPHERD TRIAL.  // Biotech Business;Nov2006, Vol. 19 Issue 11, p1 

    The article reports on the completion of the phase III shepherd trial of eculizumab by Alexion Pharmaceuticals, Inc. in Cheshire, Connecticut. It offers information on monoclonal antibody eculizumab, shepherd trial and paroxysmal nocturnal hemoglobinuria (PNH). The trial was conducted in...

  • American Society of Hematology 2007.  // BioWorld Today;12/11/2007, Vol. 18 Issue 239, p3 

    The article reports on the open-label clinical study conducted by Alexion Pharmaceuticals Inc. According to the Cheshire, Connecticut-based company, paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, was more likely for the general public to have than chronic kidney disease....

  • ASH 2008.  // BioWorld Today;12/9/2008, Vol. 19 Issue 238, p7 

    The article reports on the announcement by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut, that Soliris or eculizumab, a terminal complement inhibitor used in treating paroxysmal nocturnal hemoglobinuria (PNH), was associated with improved hematologic parameters. In one patient with cold...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • An Orphan's Tale. Comer, Ben // Medical Marketing & Media;Nov2009, Vol. 44 Issue 11, p48 

    The article offers information on Soliris, a drug manufactured and marketed by Alexion Pharmaceuticals Inc. in the U.S. It notes that the drug is monoclonal antibody indicated for the treatment of paroxysman nocturnal hemoglobinuria (PNH) and was designated an orphan drug by the U.S. Food and...

  • In the pipeline.  // Drug Utilization Review;Mar2002, Vol. 18 Issue 3, p24 

    Presents an update on the clinical trials of some drugs as of March 2002. Start on the Phase II trial of Interferon gamma-1b injection for cirrhosis by InterMune company; Launch of the Phase I clinical trial of Adeno Interferon gamma drug for cutaneous lymphoma by Transgene company; Completion...

  • CLINIC ROUNDUP.  // BioWorld Today;3/21/2008, Vol. 19 Issue 56, p8 

    This section offers news briefs on clinical trials in the U.S. as of March 21, 2008. Alexion Pharmaceuticals Inc. announced the completion of enrollment of patients in its registration study to evaluate the drug Soliris for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). IDM...

  • Clinic Roundup.  // BioWorld Today;9/11/2013, Vol. 24 Issue 174, p3 

    The article presents updates on biopharmaceutical companies as of September 11, 2013. Swiss-based Actelion Ltd. has announced that it will launch a Phase III program to evaluate the efficacy and safety of cadazolid in patients presenting with Clostridium difficile-associated diarrhea. Alexion...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics